Effect of Danggui Shaoyao San with Huangqi on adriamycin-induced nephrotic syndrome in rats

Objective:To determine the therapeutic effect of Danggui Shaoyao San with Huangqi on rats with nephrotic syndrome(NS)was discussed,and the scientific connotation of TCM treatment principle was elaborated,so as to provide experimental basis for its clinical application.Methods:The NS rat model was established by iv administration of adriamycin;The rats were divided into model group,Danggui Shaoyao San group,Danggui Shaoyao San with Huangqi group,Huangqi group and positive drug group,with 10 rats in control group;The best dosage ratio of Danggui Shaoyao San and Huangqi was screened by Excel;24 h urine protein was measured by BCA method;The electrolyte level was detected by automatic biochemical analyzer;In serum Urea nitrogen(BUN),Creatinine(SCr),Total cholesterol(TC),Triglyceride(TG),Total protein(TP),Albumin(ALB),Immunoglobulin M(Ig-M)and Immunoglobulin G(Ig-G)were detected by the kit;hematoxylin-eosin staining was used to observe the renal morphology;The Total water content(TBW),Extracellular water content(ECF)and Intracellular water content(ICF)were measured by experimental animal body composition analyzer.Results:Compared with the model group,the urine protein in the modified Astragalus group of Danggui Shaoyao Powder was significantly decreased(P<0.01);Urine electrolytes were significantly decreased and serum electrolytes were significantly increased(P<0.01);Serum BUN,SCR,TC and TG were significantly decreased(P<0.01),while TP,ALB,TBW and ICF were significantly increased(P<0.01);The levels of Ig-M and Ig-G were significantly increased(P<0.01),TBW and ICF were significantly increased,and ECF was significantly decreased(P<0.01);Histopathology showed that the pathological changes of renal tissue were obviously alleviated;The improvement of each index was better than that of Danggui Shaoyao San group and Huangqi group.Conclusion:Danggui Shaoyao San with Huangqi group can significantly improve the edema,proteinuria,blood lipid and immune function of NS rats,and the effect is better than that of Danggui Shaoyao San group and Huangqi group.It has the best therapeutic effect on NS,which indicates that Huangqi plays a key synergistic effect on Danggui Shaoyao San,which verifies the scientific connotation of"Yiqi Huoxue Lishui"in the treatment of NS.

4种治疗糖尿病周围神经病变补气活血类中成药的卫生技术评估

目的为临床选择糖尿病周围神经病变(DPN)治疗用补气活血类中成药提供参考。方法参考《医疗机构中成药遴选专家共识(第一版)》,结合临床实际,制订药物卫生技术评估细则,参考药品说明书、临床指南和文献,对4种中成药的安全性、有效性、经济性、适宜性、创新性、可及性、传承性进行评分,并计算总分。结果通心络胶囊、木丹颗粒、糖脉康颗粒、芪蛭降糖胶囊的评分分别为74.5分、72分、64.5分、57分。结论临床在选择治疗DPN的补气活血类中成药时,相对于糖脉康颗粒、芪蛭降糖胶囊,建议优先使用木丹颗粒、通心络胶囊。

王阶从“虚-痰-瘀-热-滞”论治冠状动脉狭窄经验

冠状动脉粥样硬化斑块导致冠状动脉狭窄是冠心病发病的关键和病理基础。目前,冠心病的常规治疗措施包括药物治疗和血运重建,在一定程度上能改善症状,但仍有发生不良心血管事件的风险。全国名中医王阶教授临证经验丰富,在中医辨治冠心病及用药方面独具特色。王教授提出,冠心病的核心病机是“痰瘀滞虚”,四大证候要素紧密结合,互相转化,贯穿于冠心病发生、发展的全过程。王教授认为,冠状动脉狭窄与“虚、痰、瘀、热、滞”病机密切相关,其中“虚”为内在致病之本,“血瘀、痰浊”是主要病理因素,“热毒内蕴”是重要病机,“气滞”是加重病情、干扰疾病转归的重要因素。王教授临证时强调治病求本,病机结合病理,脏腑辨证和病证结合,方证相应指导处方用药,药性结合药理,灵活配伍。治疗上,以益气补肾、活血化痰、清热解毒之法立法组方,擅用经方加减化裁,守机用之,遵旨变通;或合方治疗,兼顾病情;善用对药配伍,强化药效,颇具特色。现将王阶教授在冠状动脉狭窄治疗方面的临床经验总结如下,并附医案一则,以飨同道。

Summary of 32 Patients with Cardiac Syndrome X Treated by TCM Therapy of Regulating Qi Relieving Chest Stuffiness and Promoting Blood Circulation

Objective： To evaluate the clinical effect of Liqi Kuanxiong Huoxue method （宽胸活血,LKH, traditional Chinese medicine, TCM therapeutic method for regulating qi, relieving chest stuffiness and promoting blood circulation） in treating patients with cardiac syndrome X （CSX）. Methods： The prospective, non-randomized controlled study was conducted on 51 selected patients with CSX, who were non-randomly assigned to 2 groups, the treated group treated with LKH in addition to the conventional treatment （32 patients）, and the control group treated with conventional treatment （19 patients） like nitrate, diltiazem hydrochloride, etc. The treatment course was 14 days. The changes of such symptoms as angina pectoris, TCM syndrome and indexes of treadmill exercise test before and after treatment were observed. Results： After treatment, such symptoms as chest pain and stuffy feeling and palpitation in the treated group were improved more than those in the control group （P〈0.05）; the total effective rate on angina pectoris and TCM syndrome in the treated group was better than that in the control group （P〈0.05）. The treadmill exercise test showed that the maximal metabolic equivalent （Max MET）, the time of angina onset and ST segment depression by 0.1 mV were obviously improved after treatment in both groups, but the improvement in the treated group was better than that in the control group respectively （P〈0.05）. Conclusion： The LKH method could reduce the frequency of angina attacks and improve the clinical condition of patients with CSX.

益气活血法调控自噬延缓失神经肌萎缩的理论

周围神经损伤后骨骼肌将不可避免地发生肌肉萎缩,而气虚血瘀是失神经肌萎缩发病的主要病理机制,益气活血法是防治失神经肌萎缩的重要治则。神经损伤后局部血脉瘀滞与远端靶组织气血亏虚,可能是导致自噬溶酶体系统过度激活的主要病理机制,益气活血法(补阳还五汤)可通过益气生血与活血化瘀,恢复靶组织的气血供应,改善神经血脉瘀滞与靶组织气血亏虚的病理状态,从而抑制自噬溶酶体系统过度激活,发挥失神经肌萎缩的保护作用。

化痰通络颗粒治疗不同中医证型稳定型心绞痛的疗效观察

目的:探讨化痰通络颗粒治疗不同中医证型稳定型心绞痛(SAP)的疗效差异。方法:纳入219例瘀证SAP患者,并根据中医证型分为气虚血瘀组53例、痰瘀互结组63例、气滞血瘀组56例、痰浊闭阻组47例,另纳入50例瘀证SAP患者为对照组。所有患者均接受常规治疗,除对照组外,其余患者均在常规治疗基础上予化痰通络颗粒治疗,连续治疗4周。观察治疗前后中医证候疗效、心绞痛情况、心功能、脂代谢、凝血功能。结果:治疗后,气虚血瘀组、痰瘀互结组、气滞血瘀组、痰浊闭阻组患者疗效均优于对照组(P<0.05),且痰瘀互结组和痰浊闭阻组患者疗效均优于气虚血瘀组和气滞血瘀组(P<0.05)。治疗后,5组患者心绞痛症状积分均低于治疗前(P<0.05),且气虚血瘀组、痰瘀互结组、气滞血瘀组、痰浊闭阻组患者心绞痛症状积分均低于对照组(P<0.05),痰瘀互结组、痰浊闭阻组患者心绞痛症状积分均低于气虚血瘀组和气滞血瘀组(P<0.05)。治疗后,5组患者左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)均低于治疗前,射血分数(EF)、每搏输出量(SV)均高于治疗前(P<0.05),且痰瘀互结组、痰浊闭阻组患者LVEDD、LVESD均低于对照组,EF、SV均高于对照组(P<0.05)。治疗前痰浊闭阻组、痰瘀互结组患者总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)水平均高于气虚血瘀组、气滞血瘀组、对照组;治疗后,5组患者TC、TG、LDL均低于治疗前,HDL均高于治疗前(P<0.05)。治疗后,5组患者纤维蛋白原(FIB)、凝血酶时间(TT)均低于治疗前,活化部分凝血活酶时间(APTT)均高于治疗前,且痰瘀互结组、痰浊闭阻组患者FIB、TT水平均低于气虚血瘀组、气滞血瘀组和对照组(P<0.05)。结论:化痰通络颗粒治疗不同中医证型的稳定型心绞痛均有一定效果,联合西医治疗应用优于单独西医治疗,且其更适用于痰瘀互结证和痰浊闭阻证两种证型。

Mechanism of'Invigorating Qi and Promoting Blood Circulation'Drug Pair Ginseng-Danshen on Treatment of Ischemic Heart Disease Based on Network Pharmacology

Objective:Using network pharmacology to explore the mechanism of the'invigorating qi and promoting blood circulation'drug pair Ginseng-Danshen(Salvia miltiorrhiza)on treatment of ischemic heart disease(IHD).Methods:The chemical constituents of ginseng and Danshen drug pair were identified by searching the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP),and the potential targets of the pair were identified.The pharmacodynamics of the pair was analyzed using network pharmacology.The targets of IHD were identified by database screening.Using protein-protein interaction network,the interaction targets of Ginseng-Danshen on IHD were constructed.A"constituent-target-disease"interaction network was constructed using Cytoscape software,Gene Ontology(GO)term enrichment analysis and biological pathway enrichment analysis were carried out,and the mechanism of improving myocardial ischemia by the Ginseng-Danshen drug pair was investigated.Results:Seventeen active constituents and 53 targets were identified from ginseng,53 active constituents and 61 targets were identified from Danshen,and 32 protein targets were shared by ginseng and Danshen.Twenty GO terms were analyzed,including cytokine receptor binding,cytokine activity,heme binding,and antioxidant activity.Sixty Kyoto Encyclopedia of Genes and Genomes(KEGG)signaling pathways were analyzed,including phosphatidylinositol 3-kinase-serine-threonine kinase(PI3 K-AKT)signaling pathway,p53 signaling pathway,interleukin 17 signaling pathway,tumor necrosis factor signaling pathway,and the advanced glycation end product(AGE)-the receptor for AGE(RAGE)signaling pathway in diabetic complications.Conclusion:The specific mechanism of Ginseng-Danshen drug pair in treating IHD may be associated with improving the changes of metabolites inbody,inhibiting the production of peroxides,removing the endogenous oxygen free radicals,regulating the expression of inflammatory factors,reducing myocardial cell apoptosis and promoting vascular regeneration.

脉通君安汤治疗气虚血瘀型冠心病心绞痛的临床疗效及转录组学研究

目的观察脉通君安汤治疗气虚血瘀型冠心病心绞痛的临床疗效,并通过转录组学方法初步阐明其可能的作用机制。方法将符合纳入标准的140例气虚血瘀型冠心病心绞痛患者依据随机数字法分为治疗组、对照组各70例,治疗期间对照组脱落3例。对照组予冠心病二级预防西医基础治疗,治疗组在对照组治疗基础上加服脉通君安汤,2组疗程均为8周。治疗前后评估2组患者中医证候积分、加拿大心血管学会(Canadian cardiovascular society,CCS)心绞痛分级、西雅图量表(Seattle angina questionnaire,SAQ)评分、焦虑自评量表(Self-rating anxiety scale,SAS)评分、抑郁自评量表(Self-rating depression scale,SDS)评分及不良反应,并基于性别、年龄、病程相匹配原则选取9例患者治疗前后外周血进行转录组学测序。结果治疗后,2组患者中医证候积分均明显下降(P<0.01),治疗组在改善胸痛、胸闷、气短、神倦乏力及总分方面优于对照组(P<0.05,P<0.01);治疗组CCS心绞痛分级总改善率优于对照组(P<0.05);2组治疗前后SAQ、SAS及SDS评分均显著改善(P<0.01),治疗组SAQ评分改善优于对照组(P<0.05,P<0.01)。转录组学结果显示,治疗前后具有显著差异表达的mRNA有862个,包括509个上调,353个下调;GO分析结果显示差异表达的mRNA生物学过程有666条,主要包括病毒基因表达、翻译启动、RNA分解代谢过程等,细胞组分112条,主要包括黏着斑、核糖体亚基、核斑点等;分子功能有94条,主要包括双链RNA结合、钙黏蛋白结合、转录共调节因子活性等;KEGG分析结果显示差异mRNA富集信号通路包括20条,主要包括甘油磷脂代谢通路、单磷酸腺苷激活的蛋白激酶(AMP-activated protein kinase,AMPK)信号通路、核糖体通路等。结论脉通君安汤能够改善气虚血瘀型冠心病心绞痛患者临床症状,其作用机制为多靶点多通路,可能与甘油磷脂代谢通路、AMPK信号通路、核糖体通路的调节相关。

单味中药有效成分治疗溃疡性结肠炎研究进展

研究表明,中药治疗溃疡性结肠炎不良反应少且复发率低,临床常用益气健脾、清热祛湿、活血化瘀、补血养阴类中药组方治疗,其主要药物的有效成分具有减轻炎症反应、修复黏膜损伤、调节肠道微生态、调节免疫反应等作用。本文对常用单味中药有效成分治疗溃疡性结肠炎的作用机制进行综述,为其临床治疗与中药新药研发提供参考。

从“虚”“郁”论治高血压前期

高血压前期是高血压病的潜伏期,已经出现代谢异常、血流动力学改变等亚健康状态。高血压前期病因病机与“虚”“郁”密切相关。脾虚是高血压前期的发病基础,气郁是病机发展的中间环节,痰、瘀、火等病理产物是发病的关键因素。治疗以健运脾胃、理气开郁为原则,化痰、活血、清热多法并用,同时注重日常调护,防治结合。

Invigorating Qi and Promoting Blood Circulation in Treatmentof Chronic Idiopathic Thrombocytopenic Purpura

Twenty patients of chronic idiopathic thrombocytopenic purpura (ITP) were treated with suchkind of Chinese herbal medicine as invigorating Qi and promoting blood circulation for 4-8 weeks. The ther-apeutic effect was observed and compared with that of the two control groups treated with prednisone and co-enzyme A respectively. In the TCM group, the number of patients with marked effect, good effect and im-provement were 2, 4 and 7, the total effective rate being 65% . This efficacy was higher than that of the co-enzyme group and lower than that of the prednisone group. The changes of antiplatelet IgG antibody and hap-toglobin were also observed in the meantime, and results showed that after TOM treatment, both of themwere decreased as disease improved.

基于“二阳结谓之消”探讨糖尿病性便秘病机及防治策略

“二阳结谓之消”语出《素问·阴阳别论篇》,是认识糖尿病性便秘的早期记载,但目前学界多据此仅从二阳(足阳明胃经、手阳明大肠经)结滞化热来解释消渴期发生便秘的病机,存在一定局限性。通过考究发现“二阳”并不单指手足阳明经脉或胃肠二腑,而是包括胃、大肠二腑及手足阳明经脉;“结”也并不完全指结热这一病邪,而是指病邪胶结难解、疾病难以治愈的程度,并且“二阳”之热易伤血脉,造成络脉瘀滞。基于对“二阳结谓之消”的重新理解,笔者认为糖尿病性便秘在糖尿病期以“热伤气阴”为主要病机,糖尿病并发症期以热伤血络、血脉瘀滞为主要病机。治疗方面,糖尿病期以清热益气养阴为本,糖尿病并发症期以活血化瘀为核心,此外还需重视体质从化,全面把握糖尿病性便秘的诊治。

从气、血、痰论治冠状动脉粥样硬化性心脏病的理论探索及临床应用

冠状动脉粥样硬化性心脏病(简称冠心病)与中医学胸痹心痛病联系密切,作为临床常见的心血管疾病目前已成为严重威胁中老年人生命健康的多发病、常见病。因此,寻找有效的冠心病防治方法已成为迫切需要。近些年来,在冠心病的治疗方式上,传统中医治疗手段已经逐渐步入主流,无论从预防、治疗及预后的任何角度,中医都有着不能替代的优势与作用。中医学在整体观的指导下,基于辨证论治的治疗思路对疾病进行干预。基于古典医籍和丰富的各家学说,并结合中医临床流行病学调查,冠心病中医证候以“阳微阴弦”即“本虚标实”为基本病机,本虚以气虚为主,标实以血瘀、痰浊为主,其中气虚、血瘀、痰浊三者关系密切。故文章以此为切入点,探究历代胸痹心痛病相关著作中关于气虚、血瘀、痰浊的致病机制及三者之间相互依存、互为因果的理论基础,从而以病机言治则,将“益气温阳”“活血化瘀”“化痰逐饮”三法作为中医治疗胸痹的大方向,三法结合,灵活辨证,既重视阴弦之标,又兼顾阳微之本。同时与现代医学相结合,述析“益气、活血、化痰”的现代医学本质,发现其与现代医学所提出的通过正性肌力、抗凝、调脂、稳定斑块等手段抑制动脉粥样硬化形成的理念不谋而合,为临床中西医结合治疗冠心病提供理论基础。通过案例介绍现代医家从气、血、痰论治冠心病的经验,以期为临床提供新思路、新方法。

基于中医血脉理论谈从脾论治糖尿病血管病变

糖尿病血管病变是糖尿病严重的慢性并发症之一,目前已成为糖尿病患者死亡和致残的主要原因,其巨额的医疗费用给家庭、社会带来沉重的经济负担。文章从血管与血脉的相关性出发,基于中医血脉理论,结合传统医学与现代医学观点,认为脾气虚,运化无力,气机不畅,脂浊不化,致痰浊、瘀血、热毒等病理产物壅滞血脉是糖尿病血管病变发生的重要原因,可累及多个靶器官。结合五脏一体观,从脾为四脏之长、脾与其他四脏的病变关系论述从脾论治糖尿病血管病变的理论依据以及古今医家从脾论治糖尿病血管病的临床思路,并将中西医思想融会贯通,突出从脾论治糖尿病血管病变的重要性。治疗上注重益气养阴、活血解毒、健脾化湿之法,为临床防治糖尿病血管病变提供新思路。

管氏针灸学术流派伤科用药规律分析

目的:系统梳理管氏针灸学术流派伤科用药规律,为流派传承及临床用药提供依据。方法:将《管氏常用中医处方与遣药圭臬》所载管氏第二代名医管庆鑫的伤科经验方分别归类并建立数据库,通过Excel进行频数统计,JAVA及Gephi软件进行可视化分析,挖掘管氏针灸学术流派伤科用药规律。结果:管氏伤科经验方共71首,其中内服方66首(含4首小方)、外用方5首。使用药物共139味,使用频次802次,使用频次10的常用药共有26味,使用关联频次≥10的药对组合54对,前5位的依次是乳香与没药、当归与红花、当归与没药、当归与乳香、当归与桃仁。在药物属性中,温、平、寒及辛、苦、甘药常用,归经前三位依次为肝经、心经、脾经。结论:管氏针灸学术流派伤科用药以活血化瘀药为主,佐以补虚药、理气药、清热药或温里药。

基于“虚气留滞”益气活血中药有效成分抗缺血性脑病炎性损伤的研究进展

缺血性脑卒中(IS)是由于大脑血管阻塞,血液循环障碍,导致脑组织缺血性坏死的一种疾病。目前,炎性损伤已被证明是IS的关键病理机制之一。近年来,益气活血中药有效成分广泛运用于IS等疾病,具有抗感染、抗氧化应激等效应。核因子-κB(NF-κB)信号通路作为关键的炎症通路之一,广泛参与IS的病理进程。本文拟以NF-κB信号通路为切入点,对益气活血中药有效成分防治IS的研究作一综述,旨在为后续使用中药有效成分干预IS炎症机制研究提供一定参考依据和思路。

基于病证结合从气血水辨治急性黄斑区神经视网膜病变

气、血、水是构成和维持目功能活动的基本物质,三者生理上同源互化、病理上交互为患,是辨治眼底病不可或缺的证候要素。基于病证结合的气血水理论,急性黄斑区神经视网膜病变主要病机为气、血、水输布和代谢障碍、目络阻塞,病位在黄斑目系络脉,与肝、脾、肾三脏密切相关,可采用中药联合针刺进行治疗。药物治疗以益气活血、利水通络法为治法,以补阳还五汤为基本方,根据气滞、血瘀、水停及肝、脾、肾脏腑功能障碍加减用药;针刺选穴以局部穴位为主、远端穴位为辅,以达益气化瘀、通络明目之功。

益气活血法治疗急性心肌梗死及并发症研究进展

气虚血瘀证为急性心肌梗死的常见证型,益气活血法作为急性心肌梗死的主要治法之一,常用于治疗急性心肌梗死后不同并发症如心绞痛、经皮冠脉介入治疗术后再狭窄、心室重构及心力衰竭等,临床效果显著。本文对益气活血法通过抑制炎症水平、改善心肌细胞凋亡与自噬、影响心肌纤维化及促进血管新生等方面治疗急性心肌梗死气虚血瘀证的作用机制进行综述,以期为益气活血法治疗急性心肌梗死气虚血瘀证的科学性与有效性提供理论参考。

基于生物信息学预测冠心病心肌梗死的诊断性生物标志物及靶向铜死亡相关基因的中药

目的冠心病(coronary heart disease,CHD)是目前全球主要的致死性疾病之一,对生物标志物的检测是目前评估冠心病进展的重要无创方法,对冠心病的诊断和二级预防有着重要意义。本研究旨在筛选冠心病心肌梗死发病进程中的诊断性生物标志物,分析该病发展过程中的铜死亡相关基因,进一步预测能调控铜死亡相关基因的中药。方法检索GEO数据库获得冠心病心肌梗死芯片数据,分析差异表达基因(Differentially expressed genes,DEGs),对差异基因进行富集分析,基于最小绝对收缩和选择算子(least absolute shrinkage and selection operator,LASSO)与随机森林(Random Forest,RF)方法筛选关键基因,构建诊断性模型并进行验证。对差异基因进行免疫细胞浸润分析,结果进一步结合加权基因共表达网络分析获得差异表达的免疫相关基因,与铜死亡基因取交集获得铜死亡免疫相关的核心(Hub)基因,分析铜死亡相关基因与诊断性基因的相关性。对铜死亡相关基因进行基因集富集分析(Gene Set Enrichment Analysis,GSEA),进一步预测调控铜死亡相关基因的中药。结果差异分析获得115个DEGs,DEGs主要富集于淋巴细胞介导的免疫,线粒体呼吸链复合体Ⅳ等生物学过程和C型凝集素受体信号通路,趋化因子信号通路。机器学习方法筛选出SNORA20、SNORA19、H4C3、SNORD81、COX7B五个诊断性基因。免疫浸润分析发现树突状细胞,巨噬细胞M2,单核细胞,中性粒细胞,自然杀伤细胞,CD4+T细胞,CD8+T细胞,γδT细胞,这也表明以上8种免疫细胞对冠心病心肌梗死的发病发挥着一定作用。加权基因共表达网络分析(Weighted correlation networkanalysis,WGCNA)结合免疫浸润分析获得358个关键模块基因,与铜死亡基因取交集获得3个铜死亡与免疫特征基因。5个诊断性基因与Hub基因的相关性分析结果显示SLC31A1与SNORA20,LIAS与SNORA19、SNORD81,MTF1与H4C3、SNORA20、SNORA19、SNORD81的表达具有相关性。GSEA分析结果提示LIAS与MTF1对NF-κB信号通路、NOD样受体信号通路、Toll样受体信号通路有显著的影响,潜在调控中药以活血化瘀、行气止痛药为主。结论SNORA20、SNORA19、H4C3、SNORD81、COX7B对冠心病心肌梗死具有一定的诊断价值。冠心病心肌梗死发病过程中铜死亡与免疫浸润相关基因的预测对中医药干预此类疾病的机制研究提供了一定的参考。

从肝“体阴而用阳”论治体位性低血压

肝“体阴而用阳”是对肝之生理功能与病理变化的高度概括。肝主藏血,其体为阴,肝主疏泄,其用为阳,知晓肝“体阴而用阳”的特性,有助于临床诊疗。体位性低血压(postural hypotension,PH)的病因多为有效循环血容量减少、体循环血管阻力降低、长期处于炎热环境、长时间站立。在肝“体阴而用阳”理论的指导下,从“体阴亏虚”“用阳不足”“肝胆火盛”“肝肾阴虚”4个方面来阐述p H。治疗上以气、血、阴、阳为纲,采取“补肝体”“调肝用”“清肝利胆”“滋养肝肾”等治法,进而为中医治疗pH提供新的临床思路。